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Fatigue is the most prevalent cancer-related symptom and has a significant adverse impact on patients’ functional ability and quality of
life. Hypotheses regarding the aetiology of cancer-related fatigue are discussed, and clinical practice guidelines for the evaluation and
management of oncology patients with fatigue are reviewed. Both nonpharmacologic and pharmacologic strategies for the
management of fatigue are summarised.
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Publications on cancer-related fatigue were identified through
Medline searches based on keywords (search terms cancer and
fatigue, cancer-related fatigue, cancer and fatigue and intervention,
cancer and fatigue and treatment) and based on authors who have
published many articles on cancer-related fatigue or cancer-related
symptom management, limited to 1966–2004. A narrative review
of reference sections from recently published journal articles,
review articles, and textbook chapters was also conducted. The
brief nature of this review article does not allow for a
comprehensive presentation of results from these searches. A
hierarchical approach was used to select publications for inclusion
in this review. When possible, priority was given to publications
that were based on the most methodologically sound research
studies. As cancer-related fatigue is still a relatively new area for
research, exploratory or pilot results are cited when results from
larger studies are not available.
Owing to increasingly earlier detection and improving therapies,
the life expectancy of people with cancer has been increasing. As a
result, cancer has become a chronic illness for most patients.
Understanding the aetiology of cancer-related symptoms and the
identification of efficacious clinical management strategies are
therefore needed. Fatigue is the most prevalent cancer-related
symptom and is associated with significant morbidity, functional
impairments and reduced quality of life. Therefore, the effective
management of fatigue would significantly reduce disease burden
associated with cancer and its treatments.
Research in the area of cancer-related fatigue lags behind
attention that has been given to cancer pain, nausea and vomiting
(Curt and Johnston, 2003; Morrow et al, 2002). Recognising this
issue, the US National Institutes of Health (NIH) recently held a
State-of-the-Science Conference on Symptom Management in
Cancer to discuss the clinical management of pain, depression
and fatigue as priorities for advancing clinical care (National
Institutes of Health, 2002).
PREVALENCE OF CANCER-RELATED FATIGUE
Fatigue has been described as a nearly universal symptom among
cancer patients by the National Comprehensive Cancer Network
(NCCN) Cancer-Related Fatigue Panel (Mock et al, 2000).
Depending on the patient sample and methodology employed, it
is estimated that approximately 60–96% of cancer patients who
are undergoing cancer treatments experience fatigue (Cella, 1998).
Fatigue is extremely common among cancer patients undergoing
cytotoxic chemotherapy, radiation therapy, bone marrow trans-
plant or treatment with biological response modifiers (Irvine et al,
1994; Dean et al, 1995; Hann et al, 1999; Jacobsen et al, 1999). For a
significant number of patients, fatigue persists after treatment is
completed. Broeckel et al (1998) examined a sample of disease-free
breast cancer patients who were a mean of 16 months
postchemotherapy, and found patients’ average fatigue to be 50%
higher than that reported by a comparison group of women who
did not have cancer. Bower et al (2003) assessed breast cancer
survivors who were an average of 2.8–3 years postdiagnosis and
found that survivors’ average level of fatigue was comparable to
that of age-matched women in the general population. Breast
cancer survivors’ fatigue scores were higher than a demographi-
cally and socioeconomically similar healthy group of women at
risk for breast cancer.
AETIOLOGY OF CANCER-RELATED FATIGUE
The pathophysiology of fatigue is poorly understood and few basic
research studies have been conducted to investigate the physio-
logical mechanisms underlying cancer-related fatigue (Gutstein,
2001). Identifying the aetiological factors that contribute to fatigue
often proves to be complicated, as multiple causes typically coexist
and may have additive effects. Figure 1 depicts the most commonly
identified causes for cancer-related fatigue. Often cited factors
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comorbid medical conditions, exacerbating comorbid symptoms
and psychosocial factors.
Morrow et al (2002) reviewed the evidence supporting four
hypotheses for cancer-related fatigue: (1) anemia, (2) abnormal-
ities in adenosine triphosphate, (3) vagal afferent activation and
(4) the interaction of cytokines and serotonin. The authors
reviewed research pertaining to each hypothesis and concluded
by highlighting findings from various independent studies that
have implicated cytokines, 5-HT, and the hypothalamic–pituitary
axis in the development of cancer-related fatigue. Kurzrock (2001)
has discussed the role of cytokine dysregulation in cancer-related
fatigue and other conditions that are commonly associated with
fatigue, such as anemia, cachexia, fever, infection and depression.
Specifically, Kurzrock (2001) discussed erythropoietin, interleukin,
tumour necrosis factor and interferon. Bower et al (2003)
compared 20 breast cancer survivors with enduring fatigue to 19
nonfatigued breast cancer survivors and their findings suggest that
persistent fatigue may be associated with a T-cell mediated
inflammatory process. Several models have been proposed for
the pathophysiology of fatigue and promising findings have been
reported in support of these models. Research in this area is
preliminary and it is clear that larger, well-designed studies are
required to definitively pinpoint the causes of fatigue and the
associated clinical implications.
DIAGNOSTIC CRITERIA FOR CANCER-RELATED
FATIGUE
The Fatigue Coalition, a multidisciplinary group of medical
practitioners, researchers and patient advocates developed diag-
nostic criteria for cancer-related fatigue, with the goal of
facilitating research and treatment planning through the avail-
ability of diagnostic criteria (Cella et al, 1998). The International
Classification of Diseases-10 (ICD-10) criteria for cancer-related
fatigue require ‘significant fatigue, diminished energy, or increased
need to rest, disproportionate to any recent change in activity
level’ to be present every day or nearly every day during the same
2-week period in the past month, as well as the presence of
additional symptoms. A few examples of the additional symptoms
that count toward a diagnosis of cancer-related fatigue include
generalised weakness, diminished concentration, insomnia or
hypersomnia and unrestorative sleep (for full criteria, see Cella
et al, 1998). Since these are proposed criteria, there may be experts
on cancer-related fatigue who would disagree with some of the
additional symptoms as counting toward a diagnosis. Symptoms
must cause clinically significant distress or impairment, be
associated with cancer or cancer therapy, and cannot be primarily
due to a comorbid psychiatric disorder. A few examples of
exclusionary psychiatric conditions are provided in the criteria.
One of the challenges in using these criteria to assess patients is
that when a psychiatric diagnosis is present, the extent to which
fatigue can be attributed to the psychiatric disorder is at the
discretion of the clinician and can be difficult to determine given
the overlap in symptomatology.
To evaluate these criteria, Cella et al (2001) interviewed 379
patients who received chemotherapy or chemotherapy plus
radiation therapy and administered diagnostic criteria. A total of
37% of respondents reported at least 2 weeks of fatigue in the
previous month and 17% of respondents met criteria for cancer-
related fatigue. Sadler et al (2002) administered diagnostic criteria
to 51 patients undergoing blood or bone marrow transplantation
and found that 21% met criteria for cancer-related fatigue.
Comparisons among independent raters demonstrated high rates
of reliability. Patients meeting criteria reported higher levels of
fatigue severity, frequency, pervasiveness, and interference with
quality of life and poorer role functioning, less vitality and more
depressive symptoms. These results support the reliability and
validity of the proposed criteria for cancer-related fatigue.
These estimates are much lower than previously reported rates
for the prevalence of fatigue. Many published reports on the
prevalence of cancer-related fatigue include individuals who report
having fatigue in prevalence estimates, regardless of the severity of
fatigue. The use of diagnostic criteria represents a more stringent
approach to estimating the prevalence of cancer-related fatigue,
thus prevalence estimates based on these criteria are lower and the
cases that are identified include participants with greater severity
of fatigue and associated functional impairments. Given the
overlap with major depressive disorder, diagnostic criteria for
cancer-related fatigue may be useful in identifying patients with
fatigue who may respond to antidepressant therapy (Jacobsen et al,
2003).
CLINICAL SIGNIFICANCE OF CANCER-RELATED
FATIGUE
Cancer-related fatigue significantly impairs patients’ quality of life
and ability to function. Based on a sample of 397 patients, 91% of
respondents with fatigue reported that fatigue prevented them
from leading a ‘normal’ life, 88% reported an alteration in their
daily routine due to fatigue, and of patients who were employed
75% changed their employment status because of their fatigue
(Curt et al, 2000). Vogelzang et al (1997) interviewed 419 cancer
patients and patients reported that fatigue adversely affected their
daily lives more than pain (61% vs 19%). However, in a
comparable survey of oncologists, respondents believed that pain
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Figure 1 Causes of fatigue (Atkinson et al, 2002; Cella et al, 1998; Portenoy and Itri, 1999).
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respectively). In addition to interfering with patients’ quality of life
and functional status, cancer-related fatigue may also disrupt
treatments for cancer. Vogelzang et al (1997) found that
approximately one-third of patients interviewed reported that
fatigue impacted patients’ concerns regarding their mortality or
compromised their hope of fighting the illness. The relationship
between symptom management and cancer treatment adherence
has been identified as a priority for investigation by the US
National Institutes of Health (2002).
CLINICAL MANAGEMENT OF CANCER-RELATED
FATIGUE
For clinical interventions to be effective, patients with fatigue who
would benefit from treatment must first be identified. The extent
to which fatigue is underassessed and undertreated has been
documented. Vogelzang et al (1997) interviewed 419 cancer
patients and found that among fatigued patients, 50% did not
discuss treatment options for fatigue with their oncologists and
only 27% reported that their oncologist offered treatment
recommendations for their fatigue. Curt et al (2000) similarly
reported that 40% of patients with fatigue did not receive any
treatment recommendations. Clinical practice guidelines for the
management of fatigue have been established (Portenoy and Itri,
1999; Mock et al, 2000). Interdisciplinary evaluation and treatment
is recommended to adequately assess and manage the complex
interaction of medical, psychological and social factors that impact
fatigue characteristics and associated decrements in quality of life.
Screening for fatigue
Depending on available resources, busy clinical settings may
benefit from implementing screening tools to identify patients with
more severe fatigue so that these patients can be targeted for in-
depth assessment and treatment. The effectiveness of single item
or brief measures to identify cancer patients who may benefit from
assessment and treatment for fatigue has been demonstrated
(Kirsh et al, 2001). National Comprehensive Cancer Network
recommends the use of a single item to assess fatigue severity on a
0–10 scale. To identify the cutoff score on a 0–10 scale that
maximises sensitivity and specificity in detecting cases of more
severe fatigue, Wagner et al (2003a) administered a single-item
screening for fatigue and a longer measure of fatigue (Functional
Assessment of Cancer Therapy – Fatigue subscale, FACT-F) to 105
outpatients who were receiving chemotherapy. A cutoff of 5 was
the optimal level for detecting ‘cases’ of clinically significant
fatigue as defined by exceeding an established threshold for
caseness on the FACT-F. The suggested cutoff of 5 can be used as a
guide for clinical practice. Additional factors should be considered
when determining the optimal cutoff score for a particular clinical
setting. Resources that are available to further assess and treat
patients with fatigue should be taken into account when deciding
on a cutoff score to target patients for more in-depth assessment
and treatment when indicated. Clinics with staff available to
conduct follow-up assessment on identified patients could afford
to set a low cutoff score to identify all patients who have fatigue
regardless of severity, whereas clinical settings with limited
resources may need to set a higher cutoff score to identify only
those patients with moderately severe to severe fatigue for focused
intervention.
Assessing patients with clinically significant fatigue
Given the diverse aetiological factors that contribute to fatigue and
its multidimensional nature, the comprehensive assessment of
patients with fatigue is required for the development of effective
treatment interventions. Clinical practice guidelines for fatigue
assessment and management emphasise the need to evaluate (1)
fatigue characteristics and (2) disease status and treatment.
Guidelines also recommend obtaining a history and physical
checkup and conducting laboratory studies as indicated to rule out
common, treatable causes of fatigue, such as anemia or thyroid
dysfunction (Portenoy and Itri, 1999; Mock et al, 2000). An in-
depth fatigue assessment should include fatigue severity, temporal
characteristics (e.g. onset, duration), exacerbating and alleviating
factors, impact on functioning and quality of life, symptom-related
distress, and other symptoms that commonly co-occur with fatigue
such as pain, menopausal symptoms, sleep disturbances, depres-
sion and cognitive dysfunction. Since fatigue is a subjective
sensation, it is important to use validated, standardised assessment
instruments. Many standardised instruments have been developed
for the assessment of fatigue and its impact on quality of life (for a
review, see Wagner and Cella, 2001).
Interventions for cancer-related fatigue
The brief nature of this article does not allow a comprehensive
review of empirical support for interventions to treat cancer-
related fatigue. Priority was given to randomised clinical trials
(RCTs) with fatigue as a primary end point. For interventions with
several published RCTs (e.g. psychosocial interventions), results
from less methodologically rigorous studies were not presented.
For interventions that have not been as extensively investigated,
open-label studies and pilot studies are cited. Clinical practice
guidelines developed by the NCCN Cancer-Related Fatigue Panel
(Mock et al, 2000) through evidence-based and consensus review
are used to guide the discussion.
National Comprehensive Cancer Network Cancer-Related Fati-
gue Guidelines recommend a two-stage approach to the treatment
of cancer-related fatigue. The first step in treating fatigued cancer
patients is to identify and address any treatable contributing
factors that may be causing the fatigue. National Comprehensive
Cancer Network guidelines identify several commonly observed
treatable contributing factors, including pain, emotional distress,
anemia, sleep disturbance, nutritional inadequacies, decondition-
ing due to decreased activity and comorbidities (e.g. infection,
cardiac dysfunction, renal dysfunction). Significant improvements
in quality of life have been demonstrated among anemic cancer
patients after treatment with erythropoietic agents (Demetri et al,
1998; Cella et al, in press).
Based on NCCN guidelines, the second step involves the
management of any residual fatigue that continues after treatable
contributing factors have been resolved or fatigue that continues
despite the lack of any identified treatable contributing factors. To
place treatment strategies in the context of the patient’s clinical
status, separate algorithms are provided for patients receiving
active cancer treatment, patients receiving disease-free long-term
follow-up, and patients receiving care at the end of life. Fatigue
management includes providing education and counselling to
patients and their families, self-management strategies that
patients can utilise, nonpharmacologic interventions and pharma-
cologic treatments. Education and counselling should emphasise
that fatigue is commonly experienced by patients undergoing
treatment for cancer and is not necessarily an indicator of disease
progression (if appropriate). National Comprehensive Cancer
Network guidelines identify several strategies that patients may
find useful for managing their fatigue, including energy conserva-
tion techniques such as prioritising activities, pacing (alternating
physically demanding with more sedentary activities), scheduling
activities at times of peak energy, taking naps as long as they do
not interfere with night-time sleep and following a structured daily
routine. Distraction through engaging in pleasurable activities is
also recommended. Barsevick et al (2004) randomised cancer
patients who were initiating chemotherapy or radiotherapy to an
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tion (n¼200) or to a control intervention that was similar in terms
of time and attention (n¼196). Both interventions included three
telephone sessions with an oncology nurse during the first 3–5
weeks of treatment. A statistically significant difference in fatigue
over time was reported, with ECAM participants reporting a
greater decrease in fatigue over time compared to control partici-
pants. No differences in functional performance were observed.
National Comprehensive Cancer Network guidelines recom-
mend the following nonpharmacologic interventions: exercise,
restorative therapy, nutrition consultation, sleep hygiene and
psychosocial interventions. Of these interventions, the effective-
ness of exercise in reducing fatigue and increasing functional
abilities has received the most empirical support. Table 1
summarises results from six studies that examined exercise to
treat cancer-related fatigue, four of which were randomised,
controlled trials. Reductions in fatigue were reported from all six
trials. Types of exercise included a home-based walking pro-
gramme, a bed cycle ergometer, resistance exercise or patient-
selected exercise. It is important to highlight the strength of the
empirical support for exercise in treating cancer-related fatigue,
since the most common treatment recommendation given to
patients by their health care providers was bed rest and relaxation
(Curt et al, 2000). According to NCCN guidelines, contraindica-
tions to exercise include bone metastases, neutropenia, thrombo-
cytopenia and fever.
Psychosocial interventions have also received empirical support
for the treatment of cancer-related fatigue, as demonstrated in
Table 2. Seven randomised clinical trials to evaluate supportive
interventions (group and individual), education and stress
management groups, coping strategies training and behavioural
interventions to assist patients with managing their fatigue have
been published with impressive results. Given et al (2004)
conducted a randomised clinical trial to evaluate a cognitive
behavioural intervention to reduce cancer-related symptom
burden. The investigators found that a 20-week (10 contacts)
cognitive behavioural intervention demonstrated significant im-
pact on severity of cancer-related symptoms after four contacts (10
weeks), and this reduction was maintained at 20 weeks among
those patients who entered the trial with moderate to severe
symptoms.
Pharmacological interventions may also be useful for the
management of cancer-related fatigue, although research in this
area is limited since the few studies that have been published have
methodological shortcomings (Portenoy and Itri, 1999). Classes of
potentially useful medications include erythropoietic agents (when
anemia is present), psychostimulants, selective serotonin-reuptake
inhibitors and low-dose corticosteroids. Dosing guidelines for
erythropoietic agents to treat anemia have been established (see
NCCN Cancer and Treatment-Related Anemia guidelines as an
example, www.nccn.org).
Table 3 summarises research on the efficacy of psychostimulants
in treating fatigue among cancer patients, the elderly and patients
with multiple sclerosis. Examples of psychostimulants include
methylphenidate, modafinil, pemoline and dextroamphetamine.
Controlled, randomised trials have yielded evidence to support the
Table 1 Nonpharmacological interventions: exercise
Author Sample characteristics Sample size Design Type of exercise Results
Dimeo et al (1999) Mixed (Hem and solid
tumour)
59 RCT Bed cycle ergometer (biking) k Fatigue
Mock et al (2001) Breast cancer Stage I–III 52 RCT Home-based walking programme 4–
5  week
 1 for 30min
k Fatigue, m walking ability
Mock et al (2002) Breast cancer Stage I–III 111 RCT Home-based walking programme 4–
5  week
 1 for 30min
k Fatigue, m walking
Schwartz et al (2001) Breast cancer Stage II 61 Within subjects Home-based walking programme or
patient choice 3–4  week
 1 for
15–30min
k Fatigue, m walking ability
Schwartz et al (2002) Melanoma patients treated
with interferon-a
12 + 16 historical
controls
Quasi-experimental Patient-selected 4  week
 1 for
15min + methylphenidate 20mg QD
k Fatigue, m functional
ability
Segal et al (2003) Prostate cancer receiving
androgen ablation
155 RCT Resistance exercise k Fatigue, m quality of life,
m muscular fitness
RCT¼randomised clinical trial.
Table 2 Nonpharmalogical interventions: psychosocial
Author Sample characteristics
Sample
size Design Type of intervention Results
Spiegel et al (1981) Breast cancer Stage IV 86 RCT Support group weekly 1 year k Fatigue, anxiety, mood
disturbance
Forester et al (1985) Mixed cancer in radiation
therapy
100 RCT Individual psychotherapy 10 weeks k Fatigue, emotional
symptoms, physical symptoms
Fawzy et al (1990) Melanoma postsurgery Stage
I–II
66 RCT Support group including education and stress
management 6 weeks
k Fatigue, depression, mood
disturbance






110 RCT Coping strategy programme k Fatigue and nausea
Given et al (2004) Mixed solid tumour and
lymphoma
237 RCT Tailored behavioural intervention 8 weeks k Fatigue and pain
Jacobsen et al (2002) Mixed cancer in chemotherapy 411 RCT Professionally or self-administered stress
management training
m Vitality and mental health
RCT¼randomised clinical trial.
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with opioid administration among cancer patients (Wilwerding
et al, 1995). Bruera et al (2003) conducted a prospective open-label
trial with advanced cancer outpatients who had fatigue 4 4( 0–1 0
scale) to evaluate the effects of patient-controlled methylphenidate
for cancer-related fatigue. FACIT-F (Functional Assessment of
Chronic Illness Therapy – Fatigue) scores and Edmonton
Symptom Assessment Scale (ESAS) scores showed significant
improvement in fatigue after 7 days of treatment, with no reported
serious side effects. Schwartz et al (2002) found that methylphe-
nidate combined with exercise reduced fatigue among interferon-
treated melanoma patients (see Table 1). The efficacy of modafinil
in treating fatigue secondary to multiple sclerosis was demon-
strated in a Phase II trial (Rammohan et al, 2002). A trial of
modafinil to treat cancer-related fatigue is currently underway.
Weinshenker et al (1992) evaluated pemoline for the treatment of
fatigue among patients with multiple sclerosis and found a trend
suggesting reduced fatigue among patients who received pemoline
compared to placebo (Po 0.06). Krupp et al (1995) conducted a
randomised, clinical trial to compare amantadine, pemoline, or
placebo for the treatment of fatigue in patients with multiple
sclerosis. Patients who received amantadine had significantly less
fatigue compared to those receiving pemoline or placebo.
However, patients receiving pemoline did not differ from patients
who received placebo in reported fatigue severity.
National Comprehensive Cancer Network guidelines recom-
mend antidepressants for fatigue management, particularly when
depression is present. While the close association between fatigue
and depression suggests that antidepressants may have a role in
treating cancer-related fatigue, research in this area has not been
supportive of this class of medications. Morrow et al (2003)
conducted a randomised, double-blind trial comparing 244
patients who received paroxetine to 235 patients treated with
placebo. Patients treated with paroxetine reported less depressive
symptoms at follow-up; however, no differences in fatigue severity
were observed.
Clinical observation and limited data from controlled trials
suggests that low-dose cortisteroids may have a role in treating
cancer-related fatigue, specifically dexamethasone and prednisone.
Bruera et al (1990) demonstrated the efficacy of megestrol acetate
to manage cachexia and multiple symptoms including fatigue
among advanced cancer patients.
In sum, pharmacological approaches to the management of
cancer-related hold promise, particularly psychostimulants. It is
clear that randomised clinical trials with all of these agents are
needed to advance the development of efficacious treatment
approaches. Table 4 summarises the current status of empirical
support for nonpharmacological and pharmacological fatigue
management strategies.
CONCLUSION
Fatigue is a symptom commonly associated with cancer and its
treatments. The mechanisms underlying the development and
maintenance of fatigue are poorly understood. Fatigue is multi-
factorial in its aetiology and manifestation. Empirical support for
exercise and psychosocial interventions for fatigue have been
reported. Pharmacological treatments currently in use are based
on limited research studies. Short-term goals of clinical research
on cancer-related fatigue should focus on an improved under-
standing of the aetiology of fatigue, relationships between fatigue
and co-occurring symptoms, and evaluating treatment interven-
tions (National Institutes of Health, 2002; Wagner et al, 2003b).
Well-designed clinical trials are urgently needed for the develop-
ment of empirically supported fatigue management strategies to
reduce the symptom burden associated with cancer.
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